PE20061428A1 - Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl - Google Patents

Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl

Info

Publication number
PE20061428A1
PE20061428A1 PE2006000312A PE2006000312A PE20061428A1 PE 20061428 A1 PE20061428 A1 PE 20061428A1 PE 2006000312 A PE2006000312 A PE 2006000312A PE 2006000312 A PE2006000312 A PE 2006000312A PE 20061428 A1 PE20061428 A1 PE 20061428A1
Authority
PE
Peru
Prior art keywords
composition
estreptococos
mpl
virus
amount
Prior art date
Application number
PE2006000312A
Other languages
English (en)
Spanish (es)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36441219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061428(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0505989A external-priority patent/GB0505989D0/en
Priority claimed from GB0506000A external-priority patent/GB0506000D0/en
Priority claimed from GB0505998A external-priority patent/GB0505998D0/en
Priority claimed from GB0506004A external-priority patent/GB0506004D0/en
Priority claimed from GB0506001A external-priority patent/GB0506001D0/en
Priority claimed from GB0510596A external-priority patent/GB0510596D0/en
Priority claimed from GB0510589A external-priority patent/GB0510589D0/en
Priority claimed from GB0510598A external-priority patent/GB0510598D0/en
Priority claimed from GB0510593A external-priority patent/GB0510593D0/en
Priority claimed from GB0510591A external-priority patent/GB0510591D0/en
Priority claimed from GB0603788A external-priority patent/GB0603788D0/en
Priority claimed from GB0603790A external-priority patent/GB0603790D0/en
Priority claimed from GB0603789A external-priority patent/GB0603789D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20061428A1 publication Critical patent/PE20061428A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2006000312A 2005-03-23 2006-03-21 Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl PE20061428A1 (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0506000A GB0506000D0 (en) 2005-03-23 2005-03-23 Novel use
GB0505998A GB0505998D0 (en) 2005-03-23 2005-03-23 Novel compositions
GB0506004A GB0506004D0 (en) 2005-03-23 2005-03-23 Compositions
GB0506001A GB0506001D0 (en) 2005-03-23 2005-03-23 Novel use
GB0505989A GB0505989D0 (en) 2005-03-23 2005-03-23 Compositions
GB0510589A GB0510589D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510596A GB0510596D0 (en) 2005-05-24 2005-05-24 Composition
GB0510598A GB0510598D0 (en) 2005-05-24 2005-05-24 Composition
GB0510593A GB0510593D0 (en) 2005-05-24 2005-05-24 Novel compositions
GB0510591A GB0510591D0 (en) 2005-05-24 2005-05-24 Novel use
GB0603788A GB0603788D0 (en) 2006-02-24 2006-02-24 Novel composition
GB0603790A GB0603790D0 (en) 2006-02-24 2006-02-24 Composition
GB0603789A GB0603789D0 (en) 2006-02-24 2006-02-24 Novel use

Publications (1)

Publication Number Publication Date
PE20061428A1 true PE20061428A1 (es) 2007-01-16

Family

ID=36441219

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2006000311A PE20061300A1 (es) 2005-03-23 2006-03-21 Composiciones inmunogenicas multivalentes que comprenden un antigeno de la gripe o preparacion antigenica en combinacion con un adyuvante de emulsion de aceite en agua
PE2006000312A PE20061428A1 (es) 2005-03-23 2006-03-21 Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
PE2006000334A PE20061387A1 (es) 2005-03-23 2006-03-23 Composiciones inmunogenicas del virus de la gripe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000311A PE20061300A1 (es) 2005-03-23 2006-03-21 Composiciones inmunogenicas multivalentes que comprenden un antigeno de la gripe o preparacion antigenica en combinacion con un adyuvante de emulsion de aceite en agua

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2006000334A PE20061387A1 (es) 2005-03-23 2006-03-23 Composiciones inmunogenicas del virus de la gripe

Country Status (24)

Country Link
US (5) US20080171063A1 (OSRAM)
EP (4) EP1861120B1 (OSRAM)
JP (4) JP5770414B2 (OSRAM)
KR (5) KR20160064249A (OSRAM)
AR (3) AR052625A1 (OSRAM)
AU (3) AU2006226543B2 (OSRAM)
CA (3) CA2602456A1 (OSRAM)
CY (1) CY1117874T1 (OSRAM)
DK (1) DK1861120T3 (OSRAM)
EA (3) EA011393B1 (OSRAM)
ES (1) ES2585810T3 (OSRAM)
HR (1) HRP20160816T1 (OSRAM)
HU (1) HUE027837T2 (OSRAM)
IL (3) IL185897A (OSRAM)
MA (3) MA29715B1 (OSRAM)
MX (3) MX2007011756A (OSRAM)
NO (3) NO20074638L (OSRAM)
NZ (2) NZ561822A (OSRAM)
PE (3) PE20061300A1 (OSRAM)
PL (1) PL1861120T3 (OSRAM)
PT (1) PT1861120T (OSRAM)
SI (1) SI1861120T1 (OSRAM)
TW (3) TW200722101A (OSRAM)
WO (3) WO2006100110A1 (OSRAM)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE279943T1 (de) * 1999-02-26 2004-11-15 Chiron Srl Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
KR20160064249A (ko) * 2005-03-23 2016-06-07 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE202006021242U1 (de) * 2005-11-04 2014-01-29 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen Phasen Tensid als Adjuvans für Spalt-Grippeimpfstoffe
ES2792398T3 (es) * 2005-11-04 2020-11-11 Seqirus Uk Ltd Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
JP2009514839A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
PT1951300E (pt) 2005-11-04 2011-09-05 Novartis Vaccines & Diagnostic Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
CA2646349A1 (en) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
KR20090016704A (ko) * 2006-06-15 2009-02-17 노파르티스 아게 보조제-보존 수회-투여 인플루엔자 접종 요법
PL2043682T3 (pl) * 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
SI2422810T1 (sl) * 2006-07-17 2015-01-30 Glaxosmithkline Biologicals S.A. Influenčno cepivo
CA2583555C (en) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Influenza vaccine
EP2433648A3 (en) * 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
US20100183667A1 (en) * 2006-10-12 2010-07-22 Glaxo Smithkline Biologicals S.A. Vaccine Comprising an Oil in Water Emulsion Adjuvant
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EP1923070A1 (en) * 2006-11-15 2008-05-21 Intervet International BV Vaccine for vaccinating feline against influenza virus
CN101553252A (zh) * 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
EP2129773B1 (en) * 2007-02-23 2013-02-13 Baylor Research Institute Therapeutic applications of activation of human antigen-presenting cells through dectin-1
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009046497A1 (en) * 2007-10-12 2009-04-16 Csl Limited Method of eliciting an immune response against pandemic influenza virus
EP2462949A3 (en) * 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
GB0810305D0 (en) † 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
WO2009071633A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
CN101998990B (zh) * 2008-03-18 2013-11-27 诺华股份有限公司 流感病毒疫苗抗原制备方法的改进
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP2310045A1 (en) * 2008-06-25 2011-04-20 Novartis AG Rapid responses to delayed booster immunisations
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
US8658176B2 (en) * 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
EP2289575B1 (de) * 2009-08-06 2017-07-05 Biotronik VI Patent AG Medizinisches Implantat enthaltend eine antioxidative Substanz
US9878036B2 (en) * 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
EP2308506A1 (en) * 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
SG10201501613SA (en) * 2009-12-03 2015-04-29 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
SG10201501611QA (en) 2009-12-03 2015-04-29 Novartis Ag Circulation of components during microfluidization and/or homogenization emulsions
BR112012013425A2 (pt) * 2009-12-03 2020-11-03 Novartis Ag filtração hidrofílica durante a fabricação de adjuvantes de vacinas
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
AU2013202690B2 (en) * 2009-12-03 2016-02-11 Seqirus UK Limited Hydrophilic filtration during manufacture of vaccine adjuvants
JP5894083B2 (ja) * 2009-12-22 2016-03-23 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
WO2011088451A1 (en) * 2010-01-15 2011-07-21 Novavax, Inc. Uses of influenza virus-like particles (vlps) for characterization of neuraminidase and hemagglutinin activity
RU2527688C2 (ru) * 2010-02-27 2014-09-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностого антигена н1n1 и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена н1n1
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
RU2652296C2 (ru) * 2012-12-28 2018-04-25 Джапан Эз Репрезентед Бай Дзе Дайректор-Дженерал Оф Нэшнл Инститьют Оф Инфекшес Дизизес Композиция назальной вакцины против гриппа
US20140335116A1 (en) * 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
CN104436157A (zh) * 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) * 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
EP3197487B1 (en) * 2014-09-26 2022-08-03 Seqirus UK Limited Vaccination of immunocompromised subjects
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP3917567A1 (en) 2019-01-30 2021-12-08 GlaxoSmithKline Biologicals SA Oil/surfactant mixtures for self-emulsification
US20230054162A1 (en) * 2019-12-20 2023-02-23 Fresenius Kabi Austria Gmbh Methods for producing oil-in-water emulsions
RU2741003C1 (ru) * 2020-03-27 2021-01-22 Евгений Дмитриевич Некрасов Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов
WO2022002783A1 (en) 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
JP2023538667A (ja) 2020-08-24 2023-09-08 サノフィ パスツール インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２感染症に対するワクチン
JP2023538665A (ja) 2020-08-24 2023-09-08 サノフィ パスツール インコーポレイテッド トコフェロール含有スクアレンエマルションアジュバントを有するｃｏｖｉｄ－１９ワクチン
KR102270165B1 (ko) 2020-10-22 2021-06-28 한국화학연구원 세정제 조성물
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20250281595A1 (en) 2021-06-28 2025-09-11 Glaxosmithkline Biologicals Sa Novel influenza antigens
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095974A (en) * 1961-10-27 1963-07-02 Anthony R Perini Collapsible book rack
US4047869A (en) * 1973-02-23 1977-09-13 Mulvany Jr R F Apparatus for forming plastic articles
FR2333610A1 (fr) * 1975-12-03 1977-07-01 Zhdanovsky Z Tyazhelogo Mash Bande-electrode a ame en poudre pour rechargement a l'aide d'un alliage resistant a l'usure
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
ES2068989T3 (es) * 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
US5092235A (en) 1989-05-24 1992-03-03 Tektronix, Inc. Pressure fixing and developing apparatus
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
WO1991013261A1 (fr) 1990-03-02 1991-09-05 Experimentalny Nauchno-Issledovatelsky Institut Metallorezhuschikh Stankov Systeme numerique d'entrainement asservi
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
EP0684838A1 (en) 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2183435C (en) 1994-02-24 2008-05-13 Craig D. Wright Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) * 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
TR200002608T2 (tr) * 1998-03-09 2000-11-21 Smithkline Beecham Biologicals S.A Kombine aşı kompozisyonları
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2330610A1 (en) 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
HUP0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
DK1091928T3 (da) 1998-06-30 2007-07-23 Om Pharma Nye acylerede pseudodipeptider, fremgangsmåde til disses fremstilling og sammensætninger, som indeholder dem
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
EP1574210B1 (en) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions with adsorbed macromolecules
FR2796290B1 (fr) 1999-07-16 2001-09-14 Cross Site Technologies Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi
FR2796291B1 (fr) 1999-07-16 2001-09-21 Cross Site Technologies Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique
FR2796289B1 (fr) 1999-07-16 2001-08-10 Cross Site Technologies Seringue sans aiguille avec injecteur a elements superposes
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2800619B1 (fr) 1999-11-05 2002-02-08 Cross Site Technologies Seringue sans aiguille avec un moyen de poussee temporairement retenu
FR2802103B1 (fr) 1999-12-08 2003-10-03 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc
FR2802102B1 (fr) 1999-12-08 2002-07-12 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un tube d'ejection a section constante
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
FR2802820B1 (fr) 1999-12-27 2002-10-18 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote
IL150756A0 (en) 2000-01-31 2003-02-12 Smithkline Beecham Biolog Novel use of hiv proteins
FR2804329B1 (fr) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un opercule contenant le principe actif
FR2804869B1 (fr) 2000-02-11 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie
FR2805749B1 (fr) 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2809626B1 (fr) 2000-05-30 2003-03-07 Poudres & Explosifs Ste Nale Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit
FR2810554B1 (fr) 2000-06-22 2003-05-16 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un reservoir modulable
FR2812202B1 (fr) 2000-07-28 2002-09-13 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
EP1201250A1 (en) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
US20040071734A1 (en) * 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
AU2003224819A1 (en) * 2002-04-01 2003-10-20 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
ATE426412T1 (de) 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
DE202005022108U1 (de) * 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
KR20160064249A (ko) * 2005-03-23 2016-06-07 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
SI2422810T1 (sl) * 2006-07-17 2015-01-30 Glaxosmithkline Biologicals S.A. Influenčno cepivo
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
US20100183667A1 (en) * 2006-10-12 2010-07-22 Glaxo Smithkline Biologicals S.A. Vaccine Comprising an Oil in Water Emulsion Adjuvant
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009071633A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition

Also Published As

Publication number Publication date
JP5869744B2 (ja) 2016-02-24
WO2006100110A1 (en) 2006-09-28
TW200700078A (en) 2007-01-01
NZ561823A (en) 2010-04-30
NO20074635L (no) 2007-12-19
EA200701786A1 (ru) 2008-04-28
AU2006226543B2 (en) 2011-10-06
NO20074638L (no) 2007-12-19
CA2601022A1 (en) 2006-09-28
PT1861120T (pt) 2016-08-18
EA011393B1 (ru) 2009-02-27
US20080171063A1 (en) 2008-07-17
CA2602456A1 (en) 2006-09-28
AR053833A1 (es) 2007-05-23
MX2007011756A (es) 2008-03-11
WO2006100109A1 (en) 2006-09-28
WO2006100111A1 (en) 2006-09-28
HRP20160816T1 (hr) 2016-08-12
PE20061300A1 (es) 2006-12-23
JP2008534466A (ja) 2008-08-28
EP1861120A1 (en) 2007-12-05
US20110287054A1 (en) 2011-11-24
US20080181911A1 (en) 2008-07-31
IL185906A0 (en) 2008-01-06
TW200722101A (en) 2007-06-16
AU2006226459A1 (en) 2006-09-28
JP5770414B2 (ja) 2015-08-26
KR20070116650A (ko) 2007-12-10
PE20061387A1 (es) 2007-01-19
NZ561822A (en) 2010-04-30
EA200701785A1 (ru) 2008-04-28
KR20070116652A (ko) 2007-12-10
KR20140004815A (ko) 2014-01-13
IL185897A0 (en) 2008-01-06
IL185901A0 (en) 2008-01-06
SI1861120T1 (sl) 2016-09-30
AR054020A1 (es) 2007-05-30
EA011419B1 (ru) 2009-02-27
HUE027837T2 (en) 2016-11-28
MA29342B1 (fr) 2008-03-03
NO20074930L (no) 2007-12-07
US20090081253A1 (en) 2009-03-26
CA2603180A1 (en) 2006-09-28
AU2006226458B2 (en) 2012-08-30
AR052625A1 (es) 2007-03-21
US9730999B2 (en) 2017-08-15
JP2014129359A (ja) 2014-07-10
EP1861120B1 (en) 2016-05-25
EA200701787A1 (ru) 2008-08-29
US20140363474A1 (en) 2014-12-11
CA2601022C (en) 2023-03-07
JP2008534465A (ja) 2008-08-28
KR20070116651A (ko) 2007-12-10
JP2008534467A (ja) 2008-08-28
MX2007011775A (es) 2008-03-11
EP1861122A1 (en) 2007-12-05
MA29715B1 (fr) 2008-09-01
CA2603180C (en) 2015-10-13
TW200700079A (en) 2007-01-01
IL185897A (en) 2015-11-30
AU2006226543A1 (en) 2006-09-28
AU2006226458A1 (en) 2006-09-28
MA30298B1 (fr) 2009-04-01
EP2397153A1 (en) 2011-12-21
KR101916787B1 (ko) 2019-01-24
MX2007011748A (es) 2008-03-11
KR20160064249A (ko) 2016-06-07
DK1861120T3 (en) 2016-07-25
ES2585810T3 (es) 2016-10-10
EP1863529A1 (en) 2007-12-12
PL1861120T3 (pl) 2016-11-30
CY1117874T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
PE20061428A1 (es) Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
CO6251369A2 (es) Vacuna de influenza de emulsion de aceite en agua
AR053360A1 (es) Formulaciones novedosas de vacunas
CL2018000319A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
PE20151588A1 (es) Vacuna contra el virus del dengue
UA107940C2 (en) The vaccine composition that includes the saponin-containing adjuvant
PE20120319A1 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
NO20090062L (no) Influensavaksine
PL1951299T3 (pl) Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
CO6331297A2 (es) Composiciones adyuvantes novedosas
CR11024A (es) Adjuvantes y metodos para utilizarlos
PE20040420A1 (es) Vacunas para enfermedades reproductivas del ganado
AR067087A1 (es) Composicion de vacuna y metodo para elaborarla
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
PE20140646A1 (es) Vacuna de virus de dengue inactivado
BR112015001313A2 (pt) composições de vacina
PE20211545A1 (es) Dosis unitaria de vacuna contra el dengue y administracion de esta
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
AR076437A1 (es) Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal
CR11334A (es) Una vacuna multicomponente o monocomponente para ser utilizada cotra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado...
BR112012014689A2 (pt) composição de vacina
AR065362A1 (es) Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacunacion antigripal
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
ES2558157T3 (es) Métodos para potenciar la capacidad adyuvante de las composiciones de vacunas

Legal Events

Date Code Title Description
FC Refusal